Skip to main content

Valsartan Recalls Followed By Losartan Over NMBA Presence

Valsartan Recalls Followed By Losartan Over NMBA Presence

Valsartan Recalls Followed By Losartan Over NMBA Presence

Introduction

Macleods Pharmaceutical Limited initiated a voluntary recall over Losartan Potassium and Losartan Potassium/Hydrochlorothiazide combination due to the excessive presence of N-Nitroso-N methyl-4-aminobutyric acid (NMBA).

The first Valsartan recall was announced a year ago due to the presence of similar contaminants. Following the recall, generic drug makers continue to remove various contaminated blood pressure medications from the market. The level of NMBA detected in these tablets exceeded FDA’s much less stringent interim acceptable exposure limit of 9.82 parts per million. The exposure limit was lessened due to the resulting hypertension drug shortage. The latest announcement made on June 25, has affected  32 lots in total.

Hundreds of product liability lawsuits have been filed due to side effects of recalled valsartan, losartan, and other blood pressure drugs, by individuals diagnosed with cancer. A growing number of lawsuits are pending in District Courts across the U.S. against Valsartan. Valsartan claims are consolidated under MDL No. 2875 (In re Valsartan Products Liability Litigation) in the United States District Court, District of New Jersey, presided by Judge Robert B. Kugler, U.S.D.J and Hon. Joel Schneider, U.S.M.J.

Comments
  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

NC to Get $150M to Boost Opioid Treatment, Recovery

Categories: Opioids

North Carolina will receive an additional $150 million from Purdue Pharma and the Sackler family as part of a national $7.4 billion settlement related to the opioid

SRI Gets FDA OK for High-Dose Naloxone Trial

Categories: Opioids

SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.

The approval was granted under an Investigational New Drug (IND)…

Spokane County to Get $5M in New Opioid Settlement

Categories: Opioids

Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.

The agreement addresses the company’s role in fueling…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!